Bond Medtronix 4.625% ( US585055BD73 ) in USD

Medtronix

100 % ▲

United States

US585055BD73 ( in USD )

4.625% per year ( payment 2 times a year)

14/03/2044

Prospectus brochure of the bond Medtronic Inc US585055BD73 en USD 4.625%, maturity 14/03/2044

2 000 USD

127 117 000 USD

585055BD7

A ( Upper medium grade - Investment-grade )

A3 ( Upper medium grade - Investment-grade )

15/09/2026 ( In 180 days )

Medtronic plc is a global medical device company that develops, manufactures, and distributes medical devices and therapies used to treat a variety of chronic diseases.

The Bond issued by Medtronix ( United States ) , in USD, with the ISIN code US585055BD73, pays a coupon of 4.625% per year.
The coupons are paid 2 times per year and the Bond maturity is 14/03/2044

The Bond issued by Medtronix ( United States ) , in USD, with the ISIN code US585055BD73, was rated A3 ( Upper medium grade - Investment-grade ) by Moody's credit rating agency.

The Bond issued by Medtronix ( United States ) , in USD, with the ISIN code US585055BD73, was rated A ( Upper medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency.

Pricing Term Sheet
https://www.sec.gov/Archives/edgar/data/64670/00011931251406128...
FWP 1 d681507dfwp.htm PRICING TERM SHEET
Filed Pursuant to Rule 433
Registration No. 333-179938
Medtronic, Inc.
Pricing Term Sheet
February 20, 2014
0.875% Senior Notes due 2017
3.625% Senior Notes due 2024
4.625% Senior Notes due 2044
Issuer:
Medtronic, Inc.
Trade Date:
February 20, 2014
Settlement Date:
T+5; February 27, 2014
Denominations:
$2,000 x 1,000
Joint Bookrunners:
Barclays Capital Inc., Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated and
RBS Securities Inc.
Senior Co-Managers:
Morgan Stanley & Co. LLC and UBS Securities LLC
Co-Managers:
Mizuho Securities USA Inc., U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC
Principal Amount:
US $250,000,000
US $850,000,000
US $650,000,000
Title:
2017 Note
2024 Note
2044 Note
Security Type:
Senior Note
Senior Note
Senior Note
Ratings:*
INTENTIONALLY OMITTED
INTENTIONALLY OMITTED
INTENTIONALLY OMITTED
Maturity:
February 27, 2017
March 15, 2024
March 15, 2044
Coupon:
0.875%
3.625%
4.625%
Price to Public:
99.897%
99.806%
99.338%
Yield to Maturity:
0.910%
3.648%
4.666%
Spread to Benchmark
Treasury:
T + 20 basis points
T + 90 basis points
T + 95 basis points
Benchmark Treasury:
UST 0.625% due February, 2017
UST 2.75% due February, 2024
UST 3.75% due November,
2043
Benchmark Treasury
Yield:
0.710%
2.748%
3.716%
Interest Payment
February 27 and August 27,
March 15 and September 15,
March 15 and September 15,
Dates:
commencing
commencing
commencing
August 27, 2014
September 15, 2014
September 15, 2014
Optional Redemption: The issuer may redeem the 2017
The issuer may redeem the 2024 The issuer may redeem the 2044
Notes in whole or in part, at any
Notes in whole or in part, at any Notes in whole or in part, at any
time prior to February 27, 2017
time prior to December 15, 2023 time prior to September 15,
(their maturity date), at a
(3 months prior to their maturity 2043 (6 months prior to their
redemption price equal to the
date), at a redemption price
maturity date), at a redemption
greater of:
equal to the greater of:
price equal to the greater of:
(i) 100% of the principal
(i) 100% of the principal
(i) 100% of the principal
amount of the 2017 Notes
amount of the 2024 Notes
amount of the 2044 Notes
being redeemed; and
being redeemed; and
being redeemed; and
(ii) the sum of the present
(ii) the sum of the present
(ii) the sum of the present
values of the remaining
values of the remaining
values of the remaining
scheduled payments of
scheduled payments of
scheduled payments of
principal and interest on the
principal and interest on the
principal and interest on the
2017 Notes to be redeemed
2024 Notes to be redeemed
2044 Notes to be redeemed
(excluding any portion of
(excluding any portion of
(excluding any portion of
such payments of interest
such payments of interest
such payments of interest
accrued and paid as of the
accrued and paid as of the
accrued and paid as of the
date of redemption),
date of redemption),
date of redemption),
discounted to the
discounted to the
1 sur 2
17/11/2020 à 23:07

Pricing Term Sheet
https://www.sec.gov/Archives/edgar/data/64670/00011931251406128...
discounted to the redemption
redemption date on a semi-
redemption date on a semi-
date on a semi-annual basis
annual basis (assuming a
annual basis (assuming a
(assuming a 360-day year
360-day year consisting of
360-day year consisting of
consisting of twelve 30-day
twelve 30-day months) at
twelve 30-day months) at
months) at the adjusted
the adjusted treasury rate,
the adjusted treasury rate,
treasury rate, as described in
as described in the
as described in the
the preliminary prospectus
preliminary prospectus
preliminary prospectus
supplement, plus 5 basis
supplement, plus 15 basis
supplement, plus 15 basis
points,
points,
points,
plus, in each case, accrued and
plus, in each case, accrued and
plus, in each case, accrued and
unpaid interest to the date of
unpaid interest to the date of
unpaid interest to the date of
redemption.
redemption.
redemption.
In addition, at any time on and
In addition, at any time on and
after December 15, 2023 (3
after September 15, 2043 (6
months prior to their maturity
months prior to their maturity
date), we may at our option
date), we may at our option
redeem the 2024 Notes, in whole redeem the 2044 Notes, in whole
or in part, at a redemption price
or in part, at a redemption price
equal to 100% of the principal
equal to 100% of the principal
amount of the 2024 Notes being amount of the 2044 Notes being
redeemed, plus accrued and
redeemed, plus accrued and
unpaid interest to the date of
unpaid interest to the date of
redemption.
redemption.
CUSIP:
585055 BB1
585055 BC9
585055 BD7
ISIN:
US585055BB18
US585055BC90
US585055BD73
* An explanation of the significance of ratings may be obtained from the ratings agencies. Generally, ratings agencies
base their ratings on such material and information, and such of their own investigations, studies and assumptions,
as they deem appropriate. The security ratings above are not a recommendation to buy, sell or hold the securities
offered hereby. The ratings may be subject to review, revision, suspension, reduction or withdrawal at any time by
the rating agencies. Each of the security ratings above should be evaluated independently of any other security
rating.
The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this
communication relates. Before you invest, you should read the prospectus in that registration statement and other
documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may
get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any
underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by
contacting Barclays Capital Inc., toll free at 888-603-5847, Goldman, Sachs & Co., collect at 866-471-2526 or Merrill
Lynch, Pierce, Fenner & Smith Incorporated, toll free at 800-294-1322.
This pricing term sheet supplements the preliminary form of prospectus supplement issued by Medtronic, Inc. on
February 20, 2014 relating to its Prospectus dated March 6, 2012.
Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such
disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another email
system.
2
2 sur 2
17/11/2020 à 23:07